AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to compare the time between paracenteses before and
after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in
ovarian cancer participants with symptomatic malignant ascites.
The secondary objectives were to further assess efficacy and safety of Aflibercept treatment,
and the exploratory objectives were to assess pharmacokinetics, immunogenicity and
health-related quality of life.